# Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

> **NCT01500083** · PHASE3 · COMPLETED · sponsor: **Lundbeck Canada Inc.** · enrollment: 90 (actual)

## Conditions studied

- Indolent Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine at a dose of 100 mg/m2
- **DRUG:** Bendamustine at a dose of 120 mg/m2

## Key facts

- **NCT ID:** NCT01500083
- **Lead sponsor:** Lundbeck Canada Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2017-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500083, "Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01500083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*